Sign up for our free daily newsletter
YOUR PRIVACY - PLEASE READ CAREFULLY DATA PROTECTION STATEMENT
Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy.
Global City Media, and its associated brands will use the lawful basis of legitimate interests to use
the
contact details you have supplied to contact you regarding our publications, events, training,
reader
research, and other relevant information. We will always give you the option to opt out of our
marketing.
By clicking submit, you confirm that you understand and accept the Terms & Conditions and Privacy Policy
The firm is hoping to take advantage of the growing presence of large multinational pharmaceutical companies in the region, following industry developments that have catapulted China into a sector powerhouse.
Patent expirations
CMS’ life sciences sector group head Nick Beckett – who will lead the Beijing team – commented: ‘China is an especially attractive mergers and acquisitions destination for European and US drug-makers hoping to ride out the wave of imminent patent expirations. It is a prime location for companies looking to diversify their pipelines and make up for any shortfall.’
The launch will see CMS – which claims to have acted for 16 of the global top-20 pharma companies in the last 12 months – boost its China ranks to 30, split between offices in the capital and Shanghai.
Email your news and story ideas to: [email protected]